New pancreatic cancer drug shows promise in trial

A Redwood City-based company says its new pancreatic cancer drug could significantly improve survival rates after a successful phase 3 trial. Revolution Medicines reports daraxonrasib nearly doubled survival time and reduced the risk of death by 60% compared to chemotherapy. Dr. Brandon Huffman, a gastrointestinal oncologist from Dana-Farber Cancer Institute, joined us on 'The Nine' to discuss what this could mean for patients.